Only the combinations of romidepsin with two metabolic compounds (i.e., chloroquine and metformin) and four Bcl-2 family member inhibitors (i.e., ABT-737, venetoclax, WEHI-539, and S63845) were synergistic in chondrosarcoma cell lines. Here, BCL2 is linked to chondrosarcoma.